Question 1
Administration of filgrastim maintains the dose intensity of a treatment regimen by reducing
the:
occurrence of febrile neutropenia.
need for leucovorin rescue.
occurrence of nausea and vomiting.
risk of cardiotoxicity.
ANSWER
occurrence of febrile neutropenia.
Answer: Filgrastim is used to reduce the risk of febrile neutropenia.
Reference: Eggert, J. (Ed.). (2017). Cancer basics (2nd ed.). Pittsburgh, PA: Oncology Nursing
Society, pp. 227-228.
Question 2
Which of the following is a dose-limiting toxicity of irinotecan?
Diarrhea
Miosis
Vomiting
Alopecia
1
,ANSWER
Diarrhea
Answer: Diarrhea is the dose-limiting toxicity for irinotecan.
Reference: Polovich, M., Olsen, M., & LeFebvre, K. (Eds.). (2014). Chemotherapy and
biotherapy guidelines and recommendations for practice (4th ed.). Pittsburgh, PA: Oncology
Nursing Society, p. 44(t).
Question 3
One year after receiving total body irradiation for a hematopoietic stem cell transplant, a
patient reports increasingly dim vision and ocular sensitivity. The nurse suspects which late
effect related to treatment?
Cataracts
Macular degeneration
Strabismus
Optic nerve dysfunction
ANSWER
Cataracts
Answer: Patients who receive total body irradiation are at greater risk for the development
of cataracts.
Reference: Yarbro, C.H., Wujcik, D., & Gobel, B.H. (Eds.). (2018). Cancer nursing: Principles
and practice (8th ed.). Burlington, MA: Jones and Bartlett, p. 602.
2
, Question 4
A 78-year-old patient with prostate cancer and cardiovascular disease is taking naproxen
twice a day and a daily dose of acetylsalicylic acid. The nurse instructs the patient to:
speak with the physician about adding a cytoprotectant.
space the medications at least one hour apart.
take the medications on an empty stomach.
expect an increase in swelling of the extremities during the evening.
ANSWER
speak with the physician about adding a cytoprotectant.
Answer: Patients receiving cyclooxygenase-1 inhibitors who are high risk based on existing
cardiac disease should consider the addition of a cytoprotectant.
Reference: Yarbro, C.H., Wujcik, D., & Gobel, B.H. (Eds.). (2018). Cancer nursing: Principles
and practice (8th ed.). Burlington, MA: Jones and Bartlett, p. 801(t).
Question 5
A patient receiving a fluorouracil-based combination chemotherapy regimen is employed as
a landscaper. The nurse teaches the patient about the risk of:
photosensitivity.
pulmonary toxicity.
peripheral edema.
gout.
ANSWER
photosensitivity.
3
Administration of filgrastim maintains the dose intensity of a treatment regimen by reducing
the:
occurrence of febrile neutropenia.
need for leucovorin rescue.
occurrence of nausea and vomiting.
risk of cardiotoxicity.
ANSWER
occurrence of febrile neutropenia.
Answer: Filgrastim is used to reduce the risk of febrile neutropenia.
Reference: Eggert, J. (Ed.). (2017). Cancer basics (2nd ed.). Pittsburgh, PA: Oncology Nursing
Society, pp. 227-228.
Question 2
Which of the following is a dose-limiting toxicity of irinotecan?
Diarrhea
Miosis
Vomiting
Alopecia
1
,ANSWER
Diarrhea
Answer: Diarrhea is the dose-limiting toxicity for irinotecan.
Reference: Polovich, M., Olsen, M., & LeFebvre, K. (Eds.). (2014). Chemotherapy and
biotherapy guidelines and recommendations for practice (4th ed.). Pittsburgh, PA: Oncology
Nursing Society, p. 44(t).
Question 3
One year after receiving total body irradiation for a hematopoietic stem cell transplant, a
patient reports increasingly dim vision and ocular sensitivity. The nurse suspects which late
effect related to treatment?
Cataracts
Macular degeneration
Strabismus
Optic nerve dysfunction
ANSWER
Cataracts
Answer: Patients who receive total body irradiation are at greater risk for the development
of cataracts.
Reference: Yarbro, C.H., Wujcik, D., & Gobel, B.H. (Eds.). (2018). Cancer nursing: Principles
and practice (8th ed.). Burlington, MA: Jones and Bartlett, p. 602.
2
, Question 4
A 78-year-old patient with prostate cancer and cardiovascular disease is taking naproxen
twice a day and a daily dose of acetylsalicylic acid. The nurse instructs the patient to:
speak with the physician about adding a cytoprotectant.
space the medications at least one hour apart.
take the medications on an empty stomach.
expect an increase in swelling of the extremities during the evening.
ANSWER
speak with the physician about adding a cytoprotectant.
Answer: Patients receiving cyclooxygenase-1 inhibitors who are high risk based on existing
cardiac disease should consider the addition of a cytoprotectant.
Reference: Yarbro, C.H., Wujcik, D., & Gobel, B.H. (Eds.). (2018). Cancer nursing: Principles
and practice (8th ed.). Burlington, MA: Jones and Bartlett, p. 801(t).
Question 5
A patient receiving a fluorouracil-based combination chemotherapy regimen is employed as
a landscaper. The nurse teaches the patient about the risk of:
photosensitivity.
pulmonary toxicity.
peripheral edema.
gout.
ANSWER
photosensitivity.
3
